drugset / Trial / NCT03097211
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg
RandomizedSequentialDouble-blindTreatment
Summary
The purpose of this study was to determine whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose of immediate release levodopa/benserazide 200/50 mg or with a single-dose of immediate release levodopa/benserazide 200/50 mg plus a single-dose of nebicapone 150 mg.
Timeline
- Start
- 2006-07-17
- Primary completion
- 2006-10-20
- Completion
- 2006-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levodopa | Small molecule | 200 mg | Oral |
| Subject | Resveratrol | Small molecule | 25 mg | Oral |
| Subject | Resveratrol | Small molecule | 50 mg | Oral |
| Subject | Resveratrol | Small molecule | 75 mg | Oral |
| Subject | Resveratrol | Small molecule | 100 mg | Oral |
| Background | Nebicapone | Small molecule | 150 mg | Oral |
| Background | benserazide | Small molecule | 50 mg | Oral |